Neurological Surgery 脳神経外科40巻5号

2012年05月発行

研究

脳血管内治療における簡易血小板凝集能測定装置を用いた抗血小板薬不応性と血栓性合併症についての検討

著者： 原口健一¹ 宮地茂¹ 泉孝嗣¹ 松原功明¹ 内藤丈裕¹ 浅井琢美¹ 山之内高志¹ 若林俊彦¹

所属機関： ¹名古屋大学医学部脳神経外科

ページ範囲：P.399 - P.406

Ⅰ．はじめに

　近年明らかになっている抗血小板薬不応性の存在は，虚血性脳血管障害の再発率を上昇させ^4,18)，冠動脈疾患をはじめとした虚血性血管障害患者の予後を悪化させる^9,21,33-35)．脳血管内治療においても重要な役割をもつこれらの薬剤への不応性を克服することは，今後その治療成績を向上させるにあたって不可欠であると考えられる．われわれの施設ではベッドサイドでの簡易血小板凝集能測定装置VerifyNow^®を導入し，脳血管内治療患者の抗血小板薬不応性について検討したので，その結果に主に心血管領域からの文献的考察を加えて報告する．

参考文献

1）Accumetrics Inc., http://www.accumetrics.com/press-releases/2011may17/

SYSTEM [package insert], 2009

3）Alván G, Bechtel P, Iselius L, Gundert-Remy U：Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations：Eur J Clin Pharmacol 39：533-537, 1990

4）Bennett D, Yan B, Macgregor L, Eccleston D, Davis SM：A pilot study of resistance to aspirin in stroke patients. J Clin Neurosci 15：1204-1209, 2008

5）Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM：High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 8：2140-2148, 2010

6）Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM：Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303：754-762, 2010

7）Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM, ten Berg JM：High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 97：983-990, 2011

8）Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, Lindhardsen J, Madsen JK, Køber L, Torp-Pedersen C, Gislason GH：Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction：nationwide propensity score matched study. BMJ 342：d2690, 2011

9）Crescente M, Di Castelnuovo A, Iacoviello L, de Gaetano G, Cerletti C：PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients：a meta-analysis of 19 studies comprising 3,003 patients. Thromb Haemost 99：1129-1131, 2008

10）de Miguel Castro A, Cuellas Ramón C, Diego Nieto A, Samaniego Lampón B, Alonso Rodríguez D, Fernández Vázquez F, Alonso Orcajo N, Carbonell de Blas R, Pascual Vicente C, Pérez de Prado A：Post-treatment platelet reactivity predicts long-term adverse events better than the response to clopidogrel in patients with non-ST-segment elevation acute coronary syndrome. Rev Esp Cardiol 62：126-135, 2009

11）Dichiara J, Bliden KP, Tantry US, Chaganti SK, Kreutz RP, Gesheff TB, Kreutz Y, Gurbel PA：Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. Platelets 18：414-423, 2007

12）Feher G, Feher A, Pusch G, Koltai K, Tibold A, Gasztonyi B, Papp E, Szapary L, Kesmarky G, Toth K：Clinical importance of aspirin and clopidogrel resistance. World J Cardiol 2：171-186, 2010

13）Gasparyan AY, Watson T, Lip GY：The role of aspirin in cardiovascular prevention：implications of aspirin resistance. J Am Coll Cardiol 51：1829-1843, 2008

14）Godino C, Mendolicchio L, Figini F, Latib A, Sharp AS, Cosgrave J, Calori G, Cera M, Chieffo A, Castelli A, Maseri A, Ruggeri ZM, Colombo A：Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy? Thromb J 7：4, 2009

15）Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA：Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7：59-64, 1997

16）Hwang SJ, Jeong YH, Kim IS, Park KS, Kang MK, Koh JS, Park JR, Park Y, Koh EH, Kwak CH, Hwang JY, Kim S：Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 3：450-459, 2010

17）Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ：The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 99：409-415, 2008

18）Jeon SB, Song HS, Kim BJ, Kim HJ, Kang DW, Kim JS, Kwon SU：Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. Eur Neurol 64：51-57, 2010

19）Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM：A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180：713-718, 2009

20）Kang HS, Kwon BJ, Kim JE, Han MH：Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms：clinical implications. AJNR Am J Neuroradiol 31：1206-1210, 2010

21）Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR：Aspirin “resistance” and risk of cardiovascular morbidity：systematic review and meta-analysis. BMJ 336：195-198, 2008

22）Kubota T, Chiba K, Ishizaki T：Genotyping of S-mephenytoin 4’-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60：661-666, 1996

23）Lee DH, Arat A, Morsi H, Shaltoni H, Harris JR, Mawad ME：Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test：a single-center experience. AJNR Am J Neuroradiol 29：1389-1394, 2008

24）Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V：Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 28：315-322, 2006

25）Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V：Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer：the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 119：277-284, 2007

26）西川政勝：Medical Tribune 43：24, 2010（第19回日本心血管インターベンション治療学会）

27）Paniccia R, Antonucci E, Maggini N, Miranda M, Gori AM, Marcucci R, Giusti B, Balzi D, Prisco D, Abbate R：Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 104：287-292, 2010

28）Patrono C, García Rodríguez LA, Landolfi R, Baigent C：Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353：2373-2383, 2005

29）Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS：Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29：992-1000, 2008

30）Price MJ：Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 119：2625-2632, 2009

31）Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ；GRAVITAS Investigators：Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention：the GRAVITAS randomized trial. JAMA 305：1097-1105, 2011

32）Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B：ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention：a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47：e1-e121, 2006

33）Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV：Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events：a systematic review and meta-analysis. Arch Intern Med 167：1593-1599, 2007

34）Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV：Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting：a systematic review and meta-analysis. Am Heart J 154：221-231, 2007

35）Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF：Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis. Int J Cardiol 128：166-171, 2008

36）Tanigawa T, Nakata T, Ito M, Nishikawa M, The McLORDD Study Group：Improvement of clopidogrel hypo-responsiveness by cilostazol addition to the dual antiplatelet therapy in PCI patients carrying CYP2C19 gene polymorphism. Circulation 122 (21_MeetingAbstracts)：14257, 2010

37）Tran HA, Anand SS, Hankey GJ, Eikelboom JW：Aspirin resistance. Thromb Res 120：337-346, 2007

38）von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, Schömig A：A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 28：1814-1819, 2007